-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Eli Lilly and Company's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$28.32 B | $28.54 B | $34.12 B | $45.04 B | $65.18 B |
| Cost of Revenue |
|
$7.31 B | $6.63 B | $7.08 B | $8.42 B | $10.56 B |
| Gross Profit |
|
$21.01 B | $21.91 B | $27.04 B | $36.62 B | $54.62 B |
| Research & Development |
|
$6.93 B | $7.19 B | $9.31 B | $10.99 B | $13.34 B |
| Selling,General & Administrative |
|
$6.14 B | $6.07 B | $6.94 B | $8.13 B | $11.09 B |
| Operating Expense |
|
$13.07 B | $13.26 B | $16.25 B | $19.12 B | $24.92 B |
| Operating Income |
|
$7.93 B | $8.65 B | $10.79 B | $17.50 B | $29.70 B |
| Net Income |
|
$5.58 B | $6.24 B | $5.24 B | $10.59 B | $20.64 B |
Eli Lilly and Company's Assets vs Liabilities & Equity
Eli Lilly and Company's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$3.91 B | $2.21 B | $2.93 B | $3.42 B | $7.27 B |
| Inventories |
|
$3.89 B | $4.31 B | $5.77 B | $7.59 B | $13.74 B |
| Total Current Assets |
|
$18.45 B | $18.03 B | $25.73 B | $32.74 B | $55.63 B |
| Property,Plant and Equipment |
|
$8.99 B | $10.14 B | $12.91 B | $17.10 B | $24.68 B |
| Goodwill |
|
$3.89 B | $4.07 B | $4.94 B | $5.77 B | $5.90 B |
| Total Assets |
|
$48.81 B | $49.49 B | $64.01 B | $78.71 B | $112.48 B |
| Total Liabilities |
|
$39.65 B | $38.71 B | $53.14 B | $64.44 B | $85.94 B |
| Retained Earnings |
|
$8.96 B | $10.04 B | $10.31 B | $13.55 B | $24.47 B |
| Total Shareholder Equity |
|
$8.98 B | $10.65 B | $10.77 B | $14.19 B | $26.54 B |
| Common Stock |
|
$596.30 M | $594.10 M | $593.60 M | $592.40 M | $590.00 M |
Eli Lilly and Company's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.55 B | $1.52 B | $1.53 B | $1.77 B | $2.00 B |
| Dividends Payout |
|
-$3.09 B | -$3.54 B | -$4.07 B | -$4.68 B | -$5.38 B |
| Capital Expenditures (Capex) |
|
-$1.98 B | -$2.99 B | -$7.39 B | -$8.40 B | -$7.84 B |
| Free Cash Flow (FCF) |
|
$5.39 B | $4.60 B | -$3.15 B | $414.30 M | $8.97 B |
Eli Lilly and Company's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$21.01 B | $21.91 B | $27.04 B | $36.62 B | $54.62 B |
| Gross Profit Margin (%) |
|
74.18% | 76.77% | 79.25% | 81.31% | 83.79% |
| Operating Income |
|
$7.93 B | $8.65 B | $10.79 B | $17.50 B | $29.70 B |
| Operating Income Margin (%) |
|
28.01% | 30.32% | 31.61% | 38.86% | 45.56% |
| Net Income |
|
$5.58 B | $6.24 B | $5.24 B | $10.59 B | $20.64 B |
| Net Income Margin (%) |
|
19.71% | 21.88% | 15.36% | 23.51% | 31.66% |
| EBITDA |
|
$8.04 B | $8.66 B | $8.57 B | $15.23 B | $27.94 B |
| EBITDA Margin (%) |
|
28.40% | 30.34% | 25.11% | 33.81% | 42.86% |
Eli Lilly and Company's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
62.16% | 58.64% | 48.65% | 74.62% | - |
| Return on Assets (ROA) |
|
11.44% | 12.62% | 8.19% | 13.45% | - |
| Debt to Equity |
|
188.04% | 152.48% | 234.18% | 237.06% | 160.18% |
| Debt to total asset |
|
34.60% | 32.81% | 39.41% | 42.74% | 37.79% |
| Enterprise value to revenue |
|
9.76 | 12.68 | 16.02 | 16.11 | 0.00 |
| Enterprise value to EBITDA |
|
34.38 | 41.77 | 63.81 | 47.65 | 0.00 |
| Enterprise value |
|
$276.48 B | $361.79 B | $546.67 B | $725.64 B | - |
| Tax Rate (%) |
|
9.32% | 8.25% | 20.05% | 16.49% | 19.79% |
Frequently Asked Questions
